217 related articles for article (PubMed ID: 18372324)
1. Elocalcitol inhibits inflammatory responses in human thyroid cells and T cells.
Borgogni E; Sarchielli E; Sottili M; Santarlasci V; Cosmi L; Gelmini S; Lombardi A; Cantini G; Perigli G; Luconi M; Vannelli GB; Annunziato F; Adorini L; Serio M; Crescioli C
Endocrinology; 2008 Jul; 149(7):3626-34. PubMed ID: 18372324
[TBL] [Abstract][Full Text] [Related]
2. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes.
Crescioli C; Cosmi L; Borgogni E; Santarlasci V; Gelmini S; Sottili M; Sarchielli E; Mazzinghi B; Francalanci M; Pezzatini A; Perigli G; Vannelli GB; Annunziato F; Serio M
J Endocrinol; 2007 Oct; 195(1):145-55. PubMed ID: 17911406
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory effects of BXL-01-0029, a less hypercalcemic vitamin D analogue, in human cardiomyocytes and T cells.
Sottili M; Cosmi L; Borgogni E; Sarchielli E; Maggi L; Francalanci M; Vannelli GB; Ronconi E; Adorini L; Annunziato F; Romagnani P; Serio M; Crescioli C
Exp Cell Res; 2009 Jan; 315(2):264-73. PubMed ID: 19014933
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease.
Antonelli A; Ferrari SM; Frascerra S; Corrado A; Pupilli C; Bernini G; Benvenga S; Ferrannini E; Fallahi P
Exp Cell Res; 2011 Jul; 317(11):1527-33. PubMed ID: 21565188
[TBL] [Abstract][Full Text] [Related]
5. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.
Antonelli A; Ferrari SM; Fallahi P; Piaggi S; Paolicchi A; Franceschini SS; Salvi M; Ferrannini E
Metabolism; 2011 Feb; 60(2):277-83. PubMed ID: 20206950
[TBL] [Abstract][Full Text] [Related]
6. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.
Penna G; Fibbi B; Amuchastegui S; Corsiero E; Laverny G; Silvestrini E; Chavalmane A; Morelli A; Sarchielli E; Vannelli GB; Gacci M; Colli E; Maggi M; Adorini L
Prostate; 2009 Apr; 69(5):480-93. PubMed ID: 19107880
[TBL] [Abstract][Full Text] [Related]
7. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases.
Antonelli A; Ferrari SM; Giuggioli D; Ferrannini E; Ferri C; Fallahi P
Autoimmun Rev; 2014 Mar; 13(3):272-80. PubMed ID: 24189283
[TBL] [Abstract][Full Text] [Related]
8. Comparison between VDR analogs and current immunosuppressive drugs in relation to CXCL10 secretion by human renal tubular cells.
Sagrinati C; Sottili M; Mazzinghi B; Borgogni E; Adorini L; Serio M; Romagnani P; Crescioli C
Transpl Int; 2010 Sep; 23(9):914-23. PubMed ID: 20302596
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target.
Crescioli C; Sottili M; Bonini P; Cosmi L; Chiarugi P; Romagnani P; Vannelli GB; Colletti M; Isidori AM; Serio M; Lenzi A; Di Luigi L
Eur J Cell Biol; 2012 Feb; 91(2):139-49. PubMed ID: 22176919
[TBL] [Abstract][Full Text] [Related]
10. Interferon-γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation?
Rotondi M; Coperchini F; Pignatti P; Sideri R; Groppelli G; Leporati P; La Manna L; Magri F; Mariotti S; Chiovato L
J Clin Endocrinol Metab; 2013 Jan; 98(1):308-13. PubMed ID: 23118425
[TBL] [Abstract][Full Text] [Related]
11. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production.
Romagnani P; Maggi L; Mazzinghi B; Cosmi L; Lasagni L; Liotta F; Lazzeri E; Angeli R; Rotondi M; Filì L; Parronchi P; Serio M; Maggi E; Romagnani S; Annunziato F
J Allergy Clin Immunol; 2005 Dec; 116(6):1372-9. PubMed ID: 16337473
[TBL] [Abstract][Full Text] [Related]
12. Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease.
Inukai Y; Momobayashi A; Sugawara N; Aso Y
Eur J Endocrinol; 2007 Jun; 156(6):623-30. PubMed ID: 17535861
[TBL] [Abstract][Full Text] [Related]
13. Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10.
Hertenstein A; Schumacher T; Litzenburger U; Opitz CA; Falk CS; Serafini T; Wick W; Platten M
Biochem Pharmacol; 2011 Sep; 82(6):632-41. PubMed ID: 21703247
[TBL] [Abstract][Full Text] [Related]
14. Methimazole as an antioxidant and immunomodulator in thyroid cells: mechanisms involving interferon-gamma signaling and H(2)O(2) scavenging.
Kim H; Lee TH; Hwang YS; Bang MA; Kim KH; Suh JM; Chung HK; Yu DY; Lee KK; Kwon OY; Ro HK; Shong M
Mol Pharmacol; 2001 Nov; 60(5):972-80. PubMed ID: 11641425
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Antonelli A; Ferrari SM; Fallahi P; Frascerra S; Piaggi S; Gelmini S; Lupi C; Minuto M; Berti P; Benvenga S; Basolo F; Orlando C; Miccoli P
Endocr Relat Cancer; 2009 Dec; 16(4):1299-311. PubMed ID: 19755523
[TBL] [Abstract][Full Text] [Related]
16. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Antonelli A; Ferrari SM; Fallahi P; Frascerra S; Santini E; Franceschini SS; Ferrannini E
J Clin Endocrinol Metab; 2009 May; 94(5):1803-9. PubMed ID: 19276231
[TBL] [Abstract][Full Text] [Related]
17. Shenghua Decoction reduces uterine bleeding and regulates T-cell paradigm in human deciduas of RU486 medical abortion.
Li X; Zhang M; Wang B; Li Y; Wang L; Zhao X; Zhou X; Guo Y; Jiang G; Yao C
J Ethnopharmacol; 2013 Dec; 150(3):907-17. PubMed ID: 24140602
[TBL] [Abstract][Full Text] [Related]
18. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Antonelli A; Rotondi M; Ferrari SM; Fallahi P; Romagnani P; Franceschini SS; Serio M; Ferrannini E
J Clin Endocrinol Metab; 2006 Feb; 91(2):614-20. PubMed ID: 16303841
[TBL] [Abstract][Full Text] [Related]
19. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease.
Romagnani P; Rotondi M; Lazzeri E; Lasagni L; Francalanci M; Buonamano A; Milani S; Vitti P; Chiovato L; Tonacchera M; Bellastella A; Serio M
Am J Pathol; 2002 Jul; 161(1):195-206. PubMed ID: 12107104
[TBL] [Abstract][Full Text] [Related]
20. Pro-inflammatory effects of the Th1 chemokine CXCL10 in acquired aplastic anaemia.
Li J; Ge M; Lu S; Shi J; Li X; Wang M; Huang J; Shao Y; Huang Z; Zhang J; Nie N; Zheng Y
Cytokine; 2017 Jun; 94():45-51. PubMed ID: 28411045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
